Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Drug Profile

Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Alternative Names: Autologous-cultured-fibroblasts-RepliCel; NBDS fibroblast therapy - RepliCel; RCS-01; RCT-01; RCT-A-01; RCT-P-01; RepliCel Tendon-01; Skin aging therapy - RepliCel; Skin rejuvenation - RepliCel; Tendon repair - RepliCel

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RepliCel Life Sciences; Royal National Orthopaedic Hospital; Royal University Hospital
  • Class Fibroblast cell therapies; Skin disorder therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Tendon injuries
  • Phase I Skin aging

Most Recent Events

  • 28 Sep 2017 RepliCel terminates the phase I/IIa ReaCT trial for Tendon injuries in Canada due to slower rate of enrolment, need to obtain safety and efficacy data in a timely manner and pending expiry of manufacturing materials/reagents (Intralesional) (NCT02330146)
  • 17 Aug 2017 RepliCel Life Sciences joins MedCisions ThawSTAR® Early Adopter Program to adopt ThawSTAR® Cell Thawing Systems
  • 12 Jul 2017 RepliCel completes a phase I trial for Skin aging in Germany (NCT02391935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top